Anti-angiogenic strategies in breast cancer: An update

被引:1
|
作者
Gropper A.B. [1 ]
Mayer E.L. [1 ]
机构
[1] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
关键词
Anti-angiogenesis; Bevacizumab; Breast cancer; VEGFR inhibitor;
D O I
10.1007/s12609-010-0023-3
中图分类号
学科分类号
摘要
Angiogenesis plays a role in primary tumor growth and metastatic potential of breast cancer, and within the past decade, the development of angiogenesis inhibitors has been a significant focus of clinical research efforts. Multiple studies to date have confirmed a role for bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), in combination with chemotherapy in the treatment of metastatic breast cancer. Efforts to determine the efficacy of second-generation VEGF receptor antagonists in breast cancer patients are ongoing. In addition, trials are underway to investigate potential synergy between anti-angiogenic agents and other classes of breast cancer therapeutics and to examine the efficacy of angiogenesis inhibition in nonmetastatic disease. Preliminary work evaluating predictors of response to therapy, including serologic biomarkers, class-effect toxicity, or dynamic radiologic change, and pharmacogenetics, has been promising; however, future study is critical to best identify the patient population most likely to benefit from anti-angiogenic therapy. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码:174 / 181
页数:7
相关论文
共 50 条
  • [1] Anti-angiogenic treatment for breast cancer?
    van Netten, Johannes Pieter
    Cann, Stephen Hoption
    Thornton, Ian
    Finegan, Rory P.
    Maxwell, Chris
    [J]. CANCER TREATMENT REVIEWS, 2017, 55 : 230 - 230
  • [2] Anti-angiogenic therapy in breast cancer
    Rahman, MA
    Toi, M
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2003, 57 (10) : 463 - 470
  • [3] Novel strategies towards the use of anti-angiogenic agents in breast cancer
    Bakker, Janine L.
    Meijers-Heijboer, Hanne
    Verheul, Henk
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 717 (1-3) : 36 - 39
  • [4] Anti-angiogenic strategies for cancer therapy (review)
    Benouchan, M
    Colombo, BM
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (02) : 563 - 571
  • [5] Combined anti-proliferative and anti-angiogenic strategies for cancer
    Bar, Jair
    Onn, Amir
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (05) : 701 - 715
  • [6] Anti-angiogenic strategies in glioblastoma
    Guillamo, J. -S.
    [J]. REVUE NEUROLOGIQUE, 2011, 167 (10) : 662 - 667
  • [7] New anti-angiogenic strategies in the management of kidney cancer
    Drai, J.
    Pignot, G.
    Bessede, T.
    Bouliere, F.
    Hammoudi, Y.
    Ferlicot, S.
    Patard, J. -J.
    [J]. PROGRES EN UROLOGIE, 2013, 23 (10): : 841 - 848
  • [8] Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
    Teleanu, Raluca Ioana
    Chircov, Cristina
    Grumezescu, Alexandru Mihai
    Teleanu, Daniel Mihai
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
  • [9] Novel anti-angiogenic therapeutic strategies in colorectal cancer
    Tampellini, M.
    Sonetto, C.
    Scagliotti, G. V.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 507 - 520
  • [10] Anti-Compression and Anti-Angiogenic Therapy for Breast Cancer
    Jiang, Amanda
    Mammoto, Tadanori
    Jiang, Elisabeth
    Ingber, Donald
    Mammoto, Akiko
    [J]. FASEB JOURNAL, 2015, 29